Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
614 people get CPHD articles and Market Currents by email alert.
Get email alerts on CPHD »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
Cepheid: Awesome Company, But OverpricedDave Westenberg • Fri, Aug 10, 2012
-
-
-
Cepheid’s TB Test Looks PromisingZacks Investment Research • Mon, Sep 6, 2010 -
Cepheid Gets FDA Approval for Staph TestZacks Investment Research • Wed, Jun 9, 2010
-
Cepheid Should Benefit from New H1N1 TestZacks Investment Research • Thu, Jan 7, 2010
-
Cepheid Narrows Loss in Q3Zacks Investment Research • Mon, Nov 30, 2009
-
Cepheid: Stock Plunge Presents Buy OpportunityDouglas Cress • Tue, Jul 29, 2008 -
Cepheid Takes Hit on False MRSA Testing ClaimMichael Shulman • Wed, Mar 12, 2008 -
-
Can Cepheid Power Past $25?Marlowe Cassetti • Wed, Dec 19, 2007
-
-
FDA Approves Cepheid’s Test For Infectious BacteriaSara Calabro • Mon, Apr 23, 2007
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
Earnings Analysis For Pall Corp.: Sustainable Returns Relative To PeersCapitalCube • Fri, Sep 14, 2012 -
3 Highly Liquid Mid Caps With Strong Growth ProjectionsZetaKap • Thu, Sep 6, 2012 -
-
-
6 Liquid And High Growth Tech StocksZetaKap • Fri, Aug 10, 2012
-
-
-
-
-
-
-
6 Growing Mid-Cap Stocks With Strong LiquidityZetaKap • Wed, May 9, 2012
-
-
Hologic Must Make The Third Time A CharmStephen Simpson • Tue, May 1, 2012
-
6 Highly Shorted Tech Stocks Undervalued By EPS TrendsKapitall • Tue, Mar 20, 2012 -
-
CEPHEID's CEO Discusses Q3 2012 Results - Earnings Call TranscriptFri, Oct 19, 2012
-
Cepheid Management Discusses Q2 2012 Results - Earnings Call TranscriptThu, Jul 19, 2012
-
Cepheid Q1 2009 Earnings Call TranscriptThu, Apr 23, 2009
-
Cepheid, Q4 2008 Earnings Call TranscriptThu, Feb 5, 2009
-
Cepheid F3Q08 (Qtr End 09/30/08) Earnings Call TranscriptTue, Oct 28, 2008
-
Cepheid Second Quarter 2008 Earnings Call TranscriptThu, Jul 24, 2008
-
Cepheid Q1 2008 Earnings Call TranscriptTue, May 13, 2008
-
PR Newswire (May 7, 2013)
-
PR Newswire (May 1, 2013)
-
at MarketWatch.com (Apr 19, 2013)
-
PR Newswire (Apr 18, 2013)
-
PR Newswire (Apr 4, 2013)
-
PR Newswire (Feb 19, 2013)
-
PR Newswire (Feb 14, 2013)
-
PR Newswire (Jan 31, 2013)
-
PR Newswire (Jan 24, 2013)
-
PR Newswire (Jan 15, 2013)
-
PR Newswire (Jan 8, 2013)
-
at MarketWatch.com (Dec 27, 2012)
-
PR Newswire (Nov 28, 2012)
-
PR Newswire (Nov 5, 2012)
-
PR Newswire (Oct 25, 2012)
-
PR Newswire (Oct 18, 2012)
-
at MarketWatch.com (Sep 27, 2012)
-
at CNBC.com (Sep 27, 2012)
-
at CNBC.com (Sep 26, 2012)
CPHD vs. ETF Alternatives
Company Description
Currently, there's no company description for CPHD.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Friday, May 31, 3:52 PM Cepheid (CPHD -4.4%) slides after Jefferies analyst Brandon Couillard assumes coverage of the shares with a downgrade to Hold, but reiterates the $38 price target. Couillard says that the company is well-positioned for margin expansion over the longer term as it leverages investments in its R&D pipeline, launches new high-margined tests and captures greater manufacturing efficiencies, but present valuations are already reflecting these bullish growth expectations. Comment! [Healthcare, On the Move]
-
Thursday, April 18, 5:53 PM
After-hours top gainers, as of 5:15 p.m.: RH +8%. IMRS +6%. BGS +5%. CPHD +5%. PRLB +5%.
After-hours top losers: AIRM -15%. CIE -6%. LSCC -5%. AMD -5%. TAHO -4%. Comment! [On the Move] -
Thursday, January 24, 5:42 PM
After-hours top gainers, as of 5:15 p.m.: TPX +18%. INFA +12%. RMD +6%. KLAC +3%. QIHU +3%.
After-hours top losers: SCSS -17%. FLEX -7%. SFL -6%. ETFC -5%. CPHD -4%. Comment! [On the Move] - Tuesday, January 8, 12:42 PM Cepheid (CPHD +5.2%) ramps higher after reporting preliminary Q4 results, saying its EPS should come in just above its prior guidance of $0.10 to $0.12 a share due to a favorable revenue mix. Analysts have been expecting a $0.02 per share net loss for the quarter. Revenue is expected to be below its prior view however, driven by weaker clinical revenue from high-burden developing countries Comment! [Healthcare, On the Move, Earnings]
- Friday, January 4, 12:14 PM Cepheid (CPHD -1.8%) slips on a downgrade to Neutral at Piper Jaffray on concerns that Q4 results and its FY13 outlook could both miss expectations. The company suffered two manufacturing glitches in FY12 that impacted its ability to meet customer cartridge demand in Q3. This created a backlog and the need to put accounts on allocation as management resolved the issue. Piper thinks CPHD may have missed its end of November allocation target. The firm also cut its price target to $34 from $42. Comment! [Healthcare, On the Move]
- Friday, December 28, 2012, 12:26 PM Cepheid (CPHD +3.8%) moves up today after the company received FDA clearance for its Xpert CT/NG diagnostic test, for the rapid detection and differentiation of Chlamydia trachomatis and Neisseria gonorrhoeae. Comment! [Healthcare, On the Move]
- Thursday, September 27, 2012, 2:54 PM Goldman says Cepheid (CPHD -8.3%) is oversold, and the pullback may be a buying opportunity. The firm says that despite the gloomy FY13 margin forecast, the company has a "healthy" long-term growth story. Its a leader in the rapid MDx market, and has a solid new prduct pipeline. Comment! [Healthcare, On the Move]
-
Thursday, September 27, 2012, 12:45 PM
Midday top 10 gainers: CTC +71.53%. ROYL +31.38%. APPY +18.48%. TPX +16.5%. ULTR +15.6%. WZE +13.09%. STRM +12.7%. IGLD +12.62%. PNX +11.22%. PRAN +11.17%.
Top 10 Losers: PPHM -35.54%. CAFI -12.94%. SYUT -10.64%. CPHD -9.58%. MTE -9.02%. MITK -8.92%. CHYR -8%. CYTX -7.76%. FUL -7.37%. UBNT -7.07%. Comment! [On the Move] - Wednesday, September 26, 2012, 4:37 PM Cepheid (CPHD) guides Q3 sales lower, saying revenue is expected to be in the range of $79M to $81M, lower than targeted due to intermittent interruptions in the supply of Xpert cartridge parts. The parts availability is being addressed and Cepheid is working aggressively to ship orders. However, the company currently expects to exit the quarter with more than $5M in backorders which it expects to be fulfilled by the end of October. Shares -3% AH. 1 Comment [Healthcare, On the Move, Earnings, Tech]
- Friday, July 20, 2012, 9:58 AM Cepheid (CPHD -22%) shares plunge after Q2 earnings fell 38%, hurt by higher costs that masked strong revenue growth, and the company lowered full-year earnings targets. But Baird believes the weakness could be a buying opportunity, citing CPHD's test menu expansion, highly differentiated positioning and strong base growth; the firm rates shares at Outperform. Comment! [Healthcare, On the Move]
-
Friday, July 20, 2012, 9:15 AM
Premarket gainers: SNDK +12%. PSTI +9%. BHI +9%. SXC +8%.
Losers: CMG -19%. CPHD -15%. SAN -6%. TEF -6%. NOK -6%. VHC -5%. PNRA -5%. 2 Comments [On the Move] - Thursday, July 19, 2012, 7:26 PM Cepheid (CPHD) has resumed trading, currently changing hands at $35, -19% in the post-session. Comment! [On the Move, Healthcare]
- Monday, June 18, 2012, 2:32 PM Cepheid (CPHD +1%) continues its upward trajectory today, having gained over 17% since last Thursday. Credit Suisse says it remains a top SMID cap pick given its best-in-class diagnostic testing platform and strong secular growth trends. Shares are Outperform rated with a $45 price target. Comment! [Healthcare, On the Move]
- Tuesday, May 15, 2012, 11:00 AM Cepheid (CPHD +3.9%) gets a lift on an upgrade to Buy on valuation at UBS this morning, citing the company's solid business momentum. The firm also raises its price target raised to $45 from $44. Comment! [On the Move]
- Friday, April 20, 2012, 1:41 PM Cepheid (CPHD -5%) dips after its Q1 swings to a loss despite a jump in revenue as higher research and development expenses and input costs weighed on its bottom line. The company also gave a mixed forecast for FY12, now seeing an EPS of $0.50 - $0.55 on revenue of $333M - $347M. The Street is at $0.24 per share and revenue of $342M. Comment! [Healthcare, Earnings, On the Move]
- Thursday, April 19, 2012, 4:34 PM Cepheid (CPHD): Q1 EPS of -$0.08 may not be comparable to consensus of -$0.01. Revenue of $77.3M (+28.4% Y/Y) in-line. Shares -8.8% AH. (PR) Comment! [Earnings, Tech, On the Move]
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
The Wall Street Transcript
Diagnostic Side Expected to Have More Pricing Power, Growth Potential; Cepheid ($CPHD) a Top Pick- http://su.pr/2swUBx - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
Capitalist Bull
#LeadingStocks Down in #Volume: $FTK $MELI $CF $N $KORS $MLNX $$CPHD $INVN http://bit.ly/aew0Xf - View all 0 replies
-
- View all 0 replies
LATEST REPLIES
-
- View all 2 replies
-
-